Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 17/20 | 0.66 |
| ▸ | SMARCA2 | P51531 | 16/20 | 0.66 |
| ▸ | SMARCA4 | P51532 | 16/20 | 0.66 |
| ▸ | NR1I2 | O75469 | 6/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22776314 | 1.00 | PBRM1 (0.66) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL31748599 | 1.00 | PBRM1 (0.66) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL29704302 | 0.96 | PBRM1 (0.61) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL29704240 | 0.91 | PBRM1 (0.71) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL29704246 | 0.91 | PBRM1 (0.71) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL24514506 | 0.90 | PBRM1 (0.75) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL29704308 | 0.90 | PBRM1 (0.55) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL29704297 | 0.89 | PBRM1 (0.55) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL25109657 | 0.86 | SMARCA2 (0.52) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL29704224 | 0.86 | PBRM1 (0.58) | PBRM1SMARCA2SMARCA4NR1I2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4539849-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023244764-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |